Development of nanoscale pharmaceutical dosage forms of etoposide and their in vitro cytotoxicity assayстатья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из перечня ВАК
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 29 апреля 2021 г.
Аннотация:Novel intravenous forms of etoposide requiring no organic solvents and synthetic surfactants were developed: these were based on polymeric nanoparticle delivery systems and natural solubilizers. Subsequently, nonpolimeric forms were considered more feasible, namely the ones utilizing human serum albumin and water-soluble vitamin E (TPGS) for etoposide solubilization. The resultant compositions were stable suspensions with etoposide content not less than 1 mg/ml and particle sizes about 150 nm (albumin) and 15 nm (TPGS), respectively. The developed dosage forms performed better than existing commercial injectable form of etoposide in the in vitro tests against MCF-7 breast cancer cell lines.